Search

Your search keyword '"Wojdyla, Daniel"' showing total 1,101 results
Start Over Author "Wojdyla, Daniel"
1,101 results on '"Wojdyla, Daniel"'

54. Digoxin and Mortality in Patients With Atrial Fibrillation

Author

Lopes, Renato D., Rordorf, Roberto, De Ferrari, Gaetano M., Leonardi, Sergio, Thomas, Laine, Wojdyla, Daniel M., Ridefelt, Peter, Lawrence, John H., De Caterina, Raffaele, Vinereanu, Dragos, Hanna, Michael, Flaker, Greg, Al-Khatib, Sana M., Hohnloser, Stefan H., Alexander, John H., Granger, Christopher B., and Wallentin, Lars

Published
2018
Full Text
View/download PDF

58. Novel application of approaches to predicting medication adherence using medical claims data

Author

Zullig, Leah L., Jazowski, Shelley A., Wang, Tracy Y., Hellkamp, Anne, Wojdyla, Daniel, Thomas, Laine, Egbuonu-Davis, Lisa, Beal, Anne, and Bosworth, Hayden B.

Subjects
Sanofi S.A., Chronic diseases -- Methods, Statins -- Methods, Patient compliance -- Methods, Pharmaceutical industry -- Methods, Health care reform -- Methods, Beneficiaries, Heart attack, Antilipemic agents, Medicare, Business, Health care industry, Duke University
Abstract

Objective: To compare predictive analytic approaches to characterize medication nonadherence and determine under which circumstances each method may be best applied. Data Sources/Study Setting: Medicare Parts A, B, and D claims from 2007 to 2013. Study Design: We evaluated three statistical techniques to predict statin adherence (proportion of days covered [PDC [greater than or equal to] 80 percent]) in the year following discharge: standard logistic regression with backward selection of covariates, least absolute shrinkage and selection operator (LASSO), and random forest. We used the C-index to assess model discrimination and decile plots comparing predicted values to observed event rates to evaluate model performance. Data Extraction: We identified 11 969 beneficiaries with an acute myocardial infarction (Ml)-related admission from 2007 to 2012, who filled a statin prescription at, or shortly after, discharge. Principal Findings: In all models, prior statin use was the most important predictor of future adherence (OR = 3.65, 95% CI: 3.34-3.98; OR = 3.55). Although the LASSO regression model selected nearly 90 percent of all candidate predictors, all three analytic approaches had moderate discrimination (C-index ranging from 0.664 to 0.673). Conclusions: Although none of the models emerged as clearly superior, predictive analytics could proactively determine which patients are at risk of nonadherence, thus allowing for timely engagement in adherence-improving interventions. KEYWORDS biostatistical methods, chronic disease, medicare, 1 | INTRODUCTION Approximately half of American adults report being prescribed at least one drug in the last 30 days, and nearly one-quarter are prescribed three or more daily medications. [...]

Published
2019
Full Text
View/download PDF

61. Abstract 15664: Prior Oral Anticoagulant Status and Outcomes in Patients With Atrial Fibrillation With an Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the Augustus Trial

Author

Welsh, Robert C, Lopes, Renato D, Wojdyla, Daniel, Aronson, Ronald, Granger, Christopher B, Windecker, Stephan, Vora, Amit, Vinereanu, Dragos, Halvorsen, Sigrun, Parkhomenko, Alexander, Mehran, Roxana, Alexander, John H, and Goodman, Shaun G

Published
2020
Full Text
View/download PDF

69. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial

Author

Vora, Amit N., Alexander, John H., Wojdyla, Daniel M., Aronson, Ronald, Granger, Christopher B., Darius, Harald, Windecker, Stephan, Mehran, Roxana, Averkov, Oleg, Budaj, Andrzej, Kong, David F., Kobalava, Zhanna, Mehta, Rajendra H., Mirza, Zulfiqar, Guimaraes, Patricia Oliveira, Parkhomenko, Alexander, Quadros, Alexandre, Thiele, Holger, Goodman, Shaun G., and Lopes, Renato D.

Published
2019
Full Text
View/download PDF

72. THE EFFECT OF MAVACAMTEN TREATMENT FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN PATIENTS OF OLDER AGE AND LONGER DURATION OF DIAGNOSIS: ANALYSIS OF THE EXPLORER-HCM TRIAL

Author

Wang, Andrew, primary, Lakdawala, Neal K., additional, Abraham, Theodore P., additional, Nilles, Ester Kim, additional, Wojdyla, Daniel M., additional, Owens, Anjali Tiku, additional, Bach, Richard G., additional, Saberi, Sara, additional, Sehnert, Amy, additional, and Cresci, Sharon, additional

Published
2023
Full Text
View/download PDF

73. THE EFFECT OF MAVACAMTEN TREATMENT FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN PATIENTS WITH OR WITHOUT HYPERTENSION: ANALYSIS OF THE EXPLORER-HCM TRIAL

Author

Wang, Andrew, primary, Spertus, John A., additional, Wojdyla, Daniel M., additional, Abraham, Theodore P., additional, Nilles, Ester Kim, additional, Owens, Anjali Tiku, additional, Saberi, Sara, additional, Cresci, Sharon, additional, Sehnert, Amy, additional, and Lakdawala, Neal K., additional

Published
2023
Full Text
View/download PDF

79. Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification

Author

Toro-Domínguez, Daniel, Lopez-Domínguez, Raúl, García Moreno, Adrián, Villatoro-García, Juan A., Martorell-Marugán, Jordi, Goldman, Daniel, Petri, Michelle, Wojdyla, Daniel, Pons-Estel, Bernardo A., Isenberg, David, Morales-Montes de Oca, Gabriela, Trejo-Zambrano, María Isabel, García González, Benjamín, Rosetti, Florencia, Gómez-Martín, Diana, Romero-Díaz, Juanita, Carmona-Sáez, Pedro, and Alarcón-Riquelme, Marta E.

Published
2019
Full Text
View/download PDF

80. Predictive Accuracy of Stroke Risk Prediction Models Across Black and White Race, Sex, and Age Groups

Author

Hong, Chuan, primary, Pencina, Michael J., additional, Wojdyla, Daniel M., additional, Hall, Jennifer L., additional, Judd, Suzanne E., additional, Cary, Michael, additional, Engelhard, Matthew M., additional, Berchuck, Samuel, additional, Xian, Ying, additional, D’Agostino, Ralph, additional, Howard, George, additional, Kissela, Brett, additional, and Henao, Ricardo, additional

Published
2023
Full Text
View/download PDF

82. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Author

Carnicelli, Anthony P, Hong, Hwanhee, Connolly, Stuart J, Eikelboom, John, Giugliano, Robert P, Morrow, David A, Patel, Manesh R, Wallentin, Lars, Alexander, John H, Bahit, M Cecilia, Benz, Alexander P, Bohula, Erin A, Chao, Tze-Fan, Dyal, Leanne, Ezekowitz, Michael, Fox, Keith Aa, Gencer, Baris, Halperin, Jonathan L, Hijazi, Ziad, Hohnloser, Stefan H, Hua, Kaiyuan, Hylek, Elaine, Kato, Eri Toda, Kuder, Julia, Lopes, Renato D, Mahaffey, Kenneth W, Oldgren, Jonas, Piccini, Jonathan P, Ruff, Christian T, Steffel, Jan, Wojdyla, Daniel, and Granger, Christopher B

Subjects
Male, Network Meta-Analysis, Age Factors, Administration, Oral, Anticoagulants, Sex Factors, Risk Factors, Physiology (medical), Humans, Female, Warfarin, 610 Medicine & health, Cardiology and Cardiovascular Medicine, 360 Social problems & social services, Aged, Randomized Controlled Trials as Topic
Abstract

Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial advantages over study-level data. Methods: We used individual patient data from the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) database, which includes all patients randomized in the 4 pivotal trials of DOACs versus warfarin in atrial fibrillation (RE-LY [Randomized Evaluation of Long-Term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48]), to perform network meta-analyses using a stratified Cox model with random effects comparing standard-dose DOAC, lower-dose DOAC, and warfarin. Hazard ratios (HRs [95% CIs]) were calculated for efficacy and safety outcomes. Covariate-by-treatment interaction was estimated for categorical covariates and for age as a continuous covariate, stratified by sex. Results: A total of 71 683 patients were included (29 362 on standard-dose DOAC, 13 049 on lower-dose DOAC, and 29 272 on warfarin). Compared with warfarin, standard-dose DOACs were associated with a significantly lower hazard of stroke or systemic embolism (883/29 312 [3.01%] versus 1080/29 229 [3.69%]; HR, 0.81 [95% CI, 0.74–0.89]), death (2276/29 312 [7.76%] versus 2460/29 229 [8.42%]; HR, 0.92 [95% CI, 0.87–0.97]), and intracranial bleeding (184/29 270 [0.63%] versus 409/29 187 [1.40%]; HR, 0.45 [95% CI, 0.37–0.56]), but no statistically different hazard of major bleeding (1479/29 270 [5.05%] versus 1733/29 187 [5.94%]; HR, 0.86 [95% CI, 0.74–1.01]), whereas lower-dose DOACs were associated with no statistically different hazard of stroke or systemic embolism (531/13 049 [3.96%] versus 1080/29 229 [3.69%]; HR, 1.06 [95% CI, 0.95–1.19]) but a lower hazard of intracranial bleeding (55/12 985 [0.42%] versus 409/29 187 [1.40%]; HR, 0.28 [95% CI, 0.21–0.37]), death (1082/13 049 [8.29%] versus 2460/29 229 [8.42%]; HR, 0.90 [95% CI, 0.83–0.97]), and major bleeding (564/12 985 [4.34%] versus 1733/29 187 [5.94%]; HR, 0.63 [95% CI, 0.45–0.88]). Treatment effects for standard- and lower-dose DOACs versus warfarin were consistent across age and sex for stroke or systemic embolism and death, whereas standard-dose DOACs were favored in patients with no history of vitamin K antagonist use ( P =0.01) and lower creatinine clearance ( P =0.09). For major bleeding, standard-dose DOACs were favored in patients with lower body weight ( P =0.02). In the continuous covariate analysis, younger patients derived greater benefits from standard-dose (interaction P =0.02) and lower-dose DOACs (interaction P =0.01) versus warfarin. Conclusions: Compared with warfarin, DOACs have more favorable efficacy and safety profiles among patients with atrial fibrillation.

Published
2023

87. Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Author

Al-Khatib, Sana M., primary, Wojdyla, Daniel M., additional, Granger, Christopher B., additional, Wallentin, Lars, additional, Garcia, David A., additional, Hijazi, Ziad, additional, Held, Claes, additional, Alexander, John H., additional, Vinereanu, Dragos, additional, Flaker, Gregory C., additional, Hylek, Elaine M., additional, and Lopes, Renato D., additional

Published
2022
Full Text
View/download PDF

91. Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)

Author

Attar, Rubina, primary, Wu, Angie, additional, Wojdyla, Daniel, additional, Jensen, Svend Eggert, additional, Andell, Pontus, additional, Mahaffey, Kenneth W., additional, Roe, Matthew T., additional, James, Stefan K., additional, Wallentin, Lars, additional, Vemulapalli, Sreekanth, additional, Alexander, John H., additional, Lopes, Renato D., additional, Ohman, E. Magnus, additional, Hernandez, Adrian F., additional, Patel, Manesh R., additional, and Jones, W. Schuyler, additional

Published
2022
Full Text
View/download PDF

96. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial

Author

Kopin, David, Jones, Schuyler W., Sherwood, Matthew W., Wojdyla, Daniel M., Wallentin, Lars, Lewis, Basil S., Verheugt, Freek W.A., Vinereanu, Dragos, Bahit, Cecilia M., Halvorsen, Sigrun, Huber, Kurt, Parkhomenko, Alexander, Granger, Christopher B., Lopes, Renato D., and Alexander, John H.

Published
2018
Full Text
View/download PDF

98. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)

Author

Ugarte-Gil, Manuel Francisco, Wojdyla, Daniel, Pons-Estel, Guillermo J, Catoggio, Luis J, Drenkard, Cristina, Sarano, Judith, Berbotto, Guillermo A, Borba, Eduardo F, Sato, Emilia Inoue, Tavares Brenol, João C, Uribe, Oscar, Ramirez Gómez, Luis A, Guibert-Toledano, Marlene, Massardo, Loreto, Cardiel, Mario H, Silveira, Luis H, Chacón-Diaz, Rosa, Alarcón, Graciela S, and Pons-Estel, Bernardo A

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results